The diagnostic and prognostic utility of mitral annular plane systolic excursion (MAPSE): A systematic review

Debbie Falconer*[1,2], Fredrika Fröjdh*[3], Nikolas Wyeth[4], Daniel Brieger[5], Gaby Captur[1,2], Rebecca Kozor[5,6], Martin Ugander[3,5,6]

*Equal contribution

[1]University College London, Gower Street, London, United Kingdom

[2]Royal Free Hospital, Pond Street, London, United Kingdom

[3]Department of Clinical Physiology, Karolinska University Hospital, and Karolinska Institutet, Stockholm, Sweden

[4]Royal London Hospital, Whitechapel Road, London, United Kingdom

[5]Kolling Institute, Royal North Shore Hospital, Sydney, Australia

[6]University of Sydney, Sydney, Australia

Corresponding author:

Martin Ugander, MD, PhD

Professor of Cardiac Imaging, University of Sydney

Kolling Building, Level 12, Royal North Shore Hospital, St Leonards, Sydney, NSW 2065, Australia

Email: martin.ugander@gmail.com

Conflicts of interest: none

Funding: This work is supported in part by the British Cardiology Society/ Heart Research UK clinical fellowship. DF is also supported by the UCL-Wellington fellowship.

Abstract

Movement of the mitral annulus towards the left ventricular (LV) apex during systole, termed atrioventricular plane displacement (AVPD) or mitral annular plane systolic excursion (MAPSE), was first observed by Leonardo da Vinci in the 15th century. MAPSE, a measure of longitudinal movement, shows good agreement between transthoracic echocardiography and cardiac magnetic resonance imaging (CMR), and can also be measured by transesophageal echocardiography and gated cardiac computed tomography. Manual measurement is fast, simple, and less reliant on good echocardiographic image quality than left ventricular ejection fraction (LVEF) or global longitudinal strain (GLS). Also, measurement can be easily automated, reducing reporting time. However, no major imaging guidelines advise routine measurement. We present a systematic review of studies appraising the diagnostic and prognostic performance of MAPSE from PubMed, Medline, Google Scholar and Embase until September 2025 in accordance with the PRISMA statement. Our findings demonstrate that MAPSE correlates with both LVEF (r=0.64 [95% confidence interval 0.54–0.74]) and GLS (r=0.53 [0.45–0.63]), thus showing a modest association with measures of systolic function that may be particularly useful in patients with poor echocardiographic windows. Importantly, MAPSE falls while LVEF remains preserved across a range of pathologies, enabling earlier detection of systolic impairment than when using LVEF. MAPSE is also a powerful prognostic tool, outperforming both LVEF and GLS in predicting adverse events in several studies. Taken together, MAPSE has a clinically useful and important role that merits integration into routine cardiac imaging and care.

Keywords

Atrioventricular plane displacement (AVPD), cardiovascular magnetic resonance (CMR), transthoracic echocardiogram, mitral annular plane systolic excursion (MAPSE), left ventricular systolic dysfunction, prognosis

Abbreviations and acronyms

ACS	acute coronary syndrome
AVPD	atrioventricular plane displacement
AS	aortic stenosis
AF	atrial fibrillation
AI	artificial intelligence
ARCD	anthracycline related cardiac dysfunction
BSE	British Society of Echocardiography
CABG	coronary artery bypass graft
CI	confidence interval
CMR	cardiovascular magnetic resonance
COVID-19	coronavirus disease 2019
CT	computed tomography
DD	diastolic dysfunction
DMD	Duchenne Muscular Dystrophy
EACVI	European Association of Cardiovascular Imaging
ED	emergency department
GLS	global longitudinal strain
HCM	hypertrophic cardiomyopathy
HFpEF	heart failure with preserved ejection fraction
HFrEF	heart failure with reduced ejection fraction
HTN	hypertension
HR	hazard ratio
IHD	ischemic heart disease
LAS	left atrial strain
LFLG	low-flow low-gradient
LGE	late gadolinium enhancement
LOA	limits of agreement
LV	left ventricle
LVEF	left ventricular ejection fraction
LVH	left ventricular hypertrophy
MACE	major adverse cardiovascular event
MAPSE	mitral annular plane systolic excursion
NYHA	New York Heart Association
OR	odds ratio
PAH	pulmonary artery hypertension
PE	pulmonary embolism
POCUS	point-of-care ultrasound
TAVI	Transaortic catheter valve implantation
TDI	tissue Doppler imaging
TMAD	tissue mitral annular displacement
TTE	transthoracic echocardiography
TEE	transesophageal echocardiography
RAVI	right atrial volume index
RV	right ventricle
SCMR	Society for Cardiovascular Magnetic Resonance
STE	speckle tracking echocardiography.

Introduction

First described by Leonardo Da Vinci in the 15th Century (1), mitral annular plane systolic excursion (MAPSE) refers to the movement of the mitral annulus towards the apex during systole arising from ventricular contraction (2). MAPSE has also been referred to as movement of the mitral ring or atrioventricular plane displacement (AVPD). The term MAPSE came into common use in the early 2000s, and for simplicity, shall be used throughout this review. In the majority of patients, the cardiac apex is effectively fixed relative to the chest wall meaning long-axis contraction of the heart can be measured through the change in position of the mitral annulus. MAPSE, therefore, is a marker of longitudinal left ventricular (LV) movement, which contributes 60% of the total stroke volume (3). This proportion is constant across healthy hearts, elite athletes, and patients with dilated (4) and ischaemic cardiomyopathy, even when the absolute longitudinal function is decreased (5).

Despite a growing body of literature pointing to the usefulness of MAPSE as a measure of cardiac function, the majority of contemporary imaging protocols do not advise routine measurement, including the most recent guidelines from the British Society for Echocardiography (6) (BSE), American Society of Echocardiography (ASE) (7), European Association of Cardiovascular Imaging (EACVI) (8), and the Society for Cardiovascular Magnetic Resonance (SCMR) (9). Although the BSE recommends a single MAPSE measurement as part of a comprehensive dataset (6), it is not routinely performed in most institutions. EACVI suggests MAPSE can be measured if other markers of longitudinal function are not available (8).

Left ventricular ejection fraction (LVEF) is the mainstay for assessing systolic function, and normal LVEF can be maintained until late stages of a disease by a compensatory increase in radial function (10,11), meaning early systolic impairment is missed when assessed by LVEF alone. Global longitudinal strain (GLS) is a myocardial deformation analysis reflecting primarily longitudinal contraction, and it detects changes in systolic function before LVEF is impaired (12). Strain can be expressed as a function of the entire LV, termed long-axis strain, or on a regional basis, the latter of which has been widely adopted in cardio-oncology. Both GLS and LVEF are highly dependent on image quality. Conversely, MAPSE requires only measurement of mitral annular movement, so is less limited by imaging quality or user experience (13). MAPSE can be measured using transthoracic echocardiography (TTE) (**Figure 1**), cardiac magnetic resonance (CMR) (**Figure 2**), cardiac computer tomography (CT), and transesophageal echocardiography, and shows good agreement between modalities (14). MAPSE can also be easily automated, reducing reporting time (15). Therefore, excluding MAPSE from routine imaging may result in the loss of an easily attainable but informative imaging biomarker.

This study aimed to systematically review evidence outlining the diagnostic and prognostic utility of MAPSE in adult cardiology patients, where possible comparing its performance to LVEF and GLS. The review addresses the following clinical questions:

1. What are the normal values for MAPSE?
2. When LVEF and GLS are not available, can MAPSE be used to diagnose systolic dysfunction (i.e. how closely does MAPSE correlate to these measurements)?
3. For what pathologies can MAPSE be used to detect early systolic dysfunction in the presence of a normal LVEF?

4. In cardiovascular disease, how strongly is MAPSE associated with prognosis, and how does this compare with LVEF and GLS?

Methods

This systematic review is presented in accordance with the PRISMA statement (16). PubMed, Medline, Embase and Google Scholar were searched (terms in **supplementary material**). Retrospective and prospective observational studies assessing the diagnostic and prognostic utility of MAPSE in adult humans until September 2025 were included. Studies of healthy cohorts and those with pathology were included, and were grouped into the following categories:

1. Studies defining normal values
2. Diagnostic studies:
    a. Measuring association between MAPSE with other markers of systolic function.
    b. Comparing MAPSE in populations with a known pathology vs healthy controls where LVEF is normal.
3. Prognostic studies measuring the association between MAPSE and outcomes in cardiovascular disease and comparison with LVEF and GLS where available.

Non-English publications, abstracts and studies pertaining to congenital heart disease were excluded (**Supplementary Table S-1**). Review articles were not included, but references were manually searched for additional publications. Titles and abstracts were independently screened by both reviewers (DF and FF). If abstracts were insufficient to determine whether the publication should be included or not, the full text was read to inform the final decision

and in cases of uncertainty a third reviewer (MU) was consulted. Data from each study was extracted and tabulated by one reviewer (DF) and confirmed by another reviewer (FF). Collected data included study author and year, number of participants, pathology, imaging modality, measurement point, and outcomes. Outcomes included correlations and MAPSE values per group for diagnostic studies, and hazard ratios or odds ratios for prognostic studies as reported.

Meta-analysis of correlation coefficients (*r*) was calculated as a mean correlation [95% confidence interval] weighted by sample size to analyse overall correlation between MAPSE and LVEF or GLS using the Hunter-Schmidt method (17) in R (PsychMeta package, R version 4.2.3, 2023). Meta-correlation was calculated for each measurement site (e.g. lateral MAPSE) when reported by at least two studies. High agreement has previously been reported between CMR and TTE measurements (14), and between manual and automated approaches (15), therefore these modalities were considered sufficiently comparable to be analysed together.

For studies assessing MAPSE as a diagnostic marker when LVEF is normal and as a prognostic marker, there was substantial heterogeneity in measurement location, disease populations, and diagnostic/ prognostic criteria. Therefore, a formal meta-analysis was deemed inappropriate and the results are described narratively.

Quality Assessment

The methodological quality of included cohort and cross-sectional studies was assessed using the Newcastle-Ottawa Scale (NOS) (18) by two reviewers (DF and NW), and a third (MU) was consulted in cases of disagreement. Standard NOS criteria (**Supplementary Table S-2**) was applied to cohort studies reporting diagnostic and prognostic outcomes. For cross-

sectional studies reporting MAPSE at a single timepoint in groups with preserved LVEF, a modified version of the NOS adapted for cross-sectional studies was used as previously described (19, 20) (**Supplementary Table S-3**). The modified NOS evaluates participant selection, comparability of groups and the assessment of outcomes with a maximum score of 10 (compared with 9 for the standard NOS). Studies were then classified as high (7–9/10), moderate (5–6), or low (<5) quality.

As there are no established quality assessment tools specifically designed for studies evaluating correlation between measurements, a formal risk of bias assessment was not conducted for this group of studies.

Results

The search was performed December 2024–September 2025, and 92 studies were included **(Figure 3)**. Summaries of included studies are presented in **Tables 1–4.**

Normal MAPSE values.

Five studies (n= 3576) (**Table 1**) report MAPSE values in healthy cohorts. All studies observed an inverse relationship with age (21-25).

MAPSE as a method of diagnosing systolic impairment

1. <u>Correlation between MAPSE and other markers of systolic function.</u>

Limited echocardiographic windows can render accurate assessment of systolic function challenging. The relationship between MASPE and other markers of systolic function has been investigated to ascertain if MAPSE can be used when LVEF or GLS are not available.

Correlation between MAPSE and LVEF.

In a meta-analysis of 21 studies, LVEF and MAPSE demonstrated a moderate pooled correlation across all measurement sites (n = 2864; r = 0.64 ± 0.21 [95% CI: 0.54–0.74]) (21, 26–45); **Table 2; Figure 4**). More specifically, LVEF correlated with MAPSE measured at the lateral apical four-chamber view (n = 2011; r = 0.49 [0.27–0.70]), the mean of lateral and septal sites (n = 968; r = 0.70 [0.45–0.95]), and the mean of lateral, septal, anterior, and inferior sites (n = 366; r = 0.79 [0.56–1.00]).

Correlation between MAPSE and tissue Doppler imaging (TDI).

There was a correlation between MAPSE and tissue Doppler imaging (TDI) in 92 patients (r=0.9, p<0.001) (46) and 56 healthy subjects (r=0.56, p<0.0001) (47). Due to the limited number of studies, no meta-correlation performed was performed for this association.

Correlation between MAPSE and GLS

A meta-correlation of 15 studies (n=5078) showed a moderate pooled correlation between MAPSE and GLS (r=0.53±0.17 [0.45–0.63]) (15,22,33, 38, 48-58) (**Table 2**; **Figure 5**). Specifically, studies using lateral MAPSE alone reported a correlation of 0.45 [0.33–0.73] (n = 231), while studies using the mean of lateral and septal MAPSE reported a stronger correlation of 0.79 [0.56–1.00] (n=366). When MAPSE was measured at six points across three apical views, the correlation was 0.66 [0.46–0.87] (n=1992).

2. <u>MAPSE as a marker of reduced longitudinal systolic function when LVEF is normal</u>.

Thirty-one studies compared MAPSE in patients and controls where LVEF was normal (**Table 3**) (14, 53, 59-79, 81-88). These studies were undertaken in the following patient groups.

Hypertension (HTN) or type 2 diabetes mellitus (T2DM). Six TTE studies of subjects with HTN and/or T2DM demonstrated MAPSE was reduced compared with age and sex-matched controls (59-64). In one study, MAPSE was similar in cohorts with diabetes *or* HTN (13.5±2.3mm and 13.2±2.2mm, respectively) but lower in those with both conditions (11.5±3.0mm, $p<0.05$), suggesting a cumulative effect (61). A study of 45 patients undergoing sleeve gastrectomy showed an increase in MAPSE 6 months post-surgery (median 16mm vs 18m, $p<0.01$) which may be related to the associated reduction in HTN and DM, though several other cardiovascular risk factors were also reduced (65).

Aortic stenosis (AS). Mean MAPSE was lower in a cohort of 49 patients with AS (all grades) compared with 133 controls (9.2±2.3mm vs 10.7±2.8mm, $p<0.001$) (66). A prospective study (n=78) found lateral MAPSE was lower in patients with severe AS compared with controls ($p<0.002$) whilst septal MAPSE was lower in mild, moderate and severe AS ($p<0.001$) (67). In 58 patients undergoing surgical replacement for severe AS, MAPSE was higher in patients with no myocardial fibrosis (10.7±1.2mm) compared with mild (8.8±1.4mm, $p<0.05$) or severe (4.9±1mm, $p<0.001$) changes on biopsy at the time of surgery. Patients with no or mild fibrosis were more likely to experience an improvement in symptoms to New York Heart Association (NYHA) grade I or II, whilst patients with severe fibrosis remained in NYHA class III or IV nine months post-surgery. LVEF did not predict improvement in symptoms (68). Likewise, a study of 101 patients undergoing transcatheter aortic valve implantation reported an increase in MAPSE, but not LVEF, post-procedure (9.1±3.2 to 10.2±3.3mm,

p=0.006) (69). A study of 205 patients with severe AS showed a reduction in MAPSE of >2mm per serial scan had an increased likelihood of requiring intervention (HR 1.95 [1.04–3.66] p=0.04) when LVEF remained preserved (70). MAPSE was also lower in low-flow low-gradient severe AS compared with moderate (12.8±1.7mm vs 5.0mm±0.9mm, *p*<0.05) (71) and pseudosevere AS (9.8±2.6 vs 11.6±2.2mm, p<0.05) (72), and may assist in differentiating these groups where there is uncertainty.

HFpEF. Five studies found MAPSE is lower in patients with diastolic dysfunction (DD) than controls (53, 73-6). Rather than acting as a marker of pure DD, reduced MAPSE likely reflects concurrent longitudinal systolic dysfunction, as systolic and diastolic function are inextricably linked (13), and may result from a higher prevalence of comorbidities associated with DD such as HTN and DM. In patients with HFpEF undergoing cardiopulmonary exercise testing, MAPSE was lower at rest (10.9±2.1mm vs 12.1±2.2mm, *p*=0.008), and augmented less during exercise in patients with DD compared with controls (12±2.2mm vs 16.2±2.7mm, *p*<0.001) (53).

MAPSE was also lower in three cohorts with LV hypertrophy (LVH) (77-9). In disease states where the LV hypertrophies or dilates, less longitudinal contraction is required to generate the same stroke volume, so a reduction in MAPSE reflects both increased LV mass and size (80)..

HCM. Two CMR-based studies (14, 81) found MAPSE was lower in patients with HCM vs controls. Septal MAPSE was reduced compared with lateral MAPSE in patients with outflow obstruction (9.2±3.7mm vs 11±3.6mm, *p*=0.04) reflecting greater impairment in the septum, which is the area of greatest disease (14).

Mitral regurgitation. CT-derived MAPSE was lower in patients with severe primary mitral regurgitation (9.9±1.4mm) compared with healthy controls (11.9±1.0mm) and LVEF was preserved relative to their valve function (64±5.5% and 54±6.9% respectively). Furthermore, MAPSE fell as mitral annular calcification increased in severity (8.8±1.0mm vs 5.3±0.7mm for grade 1 and 4 respectively (82).

Marfan's syndrome. MAPSE was lower in all 5 measurement positions in a TTE study compared with controls. Of note, LVEF was also lower in the Marfan's group, but was well within normal range (66 vs 71%, $p<0.001$) (83).

Anthracycline-related cardiac disease (ARCD). Post-chemotherapy MAPSE was lower in those who did not recover systolic function compared with those with good recovery (11.7±1.5 vs 15.7±3.1mm, $p=0.03$) (84) from ARCD, suggesting MAPSE may identify those most at risk from ongoing impaired function when ARCD occurs. Of note, two studies demonstrated no difference in pre-chemotherapy MAPSE in patients who developed ARCD compared with those who did not (85, 86).

Hypothyroidism. A study of 81 patients with hypothyroidism found lateral MAPSE was lower than controls with similar rates of typical cardiovascular risk factors and normal LVEF (17±2 vs 15±3mm, p=0.002), though both groups fell within normal range. (87).

Mixed connective tissue disease (MCTD). MAPSE was lower in 77 patients with MCTD and normal LVEF and GLS compared with controls (88) (13.7±2.1 vs 15.3±2.3, p<0.001).

MAPSE as a prognostic biomarker

The prognostic capability of MAPSE has been investigated in 29 studies across a range of pathologies (**Table 4**) (15, 37, 43, 51, 52, 89–112).

General outpatient cohorts. In the largest cohort, which included individuals with pathology and normal scans undergoing outpatient CMR (n=1572), automatically-measured MAPSE was a better predictor of death or hospitalisation for heart failure (HR 1.7 [1.5–2.0] per mm decrease, p<0.001) compared with GLS (HR 1.5 [1.3–1.7] per % increase, p<0.001) or LVEF (HR 1.4 [1.2–1.6] per % decrease, p<0.001) on multivariable analysis (15). A similarly heterogeneous cohort of 400 patients followed up for 14 months, found lateral MAPSE was the strongest imaging-based predictor of MACE after multivariable analysis (HR 1.34 per 2mm decrease, p=0.02) whereas neither LVEF nor the presence of LGE remained associated (89). In a TTE-based study of 512 patients, lateral MAPSE was the only imaging-based predictor of mortality (HR 0.01 [0.00–0.52] for MAPSE ≥12 vs <12 mm, p=0.02) (43), as early as 30 days after imaging (p<0.001).

HFrEF. Multiple CMR and TTE studies have demonstrated the prognostic significance of MAPSE (90-94). The largest, a multicentre study of 1040 patients with HFrEF undergoing CMR showed lateral MAPSE was the strongest imaging-based biomarker in predicting mortality (HR 2.1 [1.5–2.8] per mm decrease, p<0.001). Presence of LGE was a weaker predictor (HR 2.0 [1.3–3.0], p=0.02) whilst LVEF was not associated. Patients with median MAPSE >9mm had a similar survival regardless of LVEF (p=0.96) (90). When compared, MAPSE outperformed LVEF (90,93) and GLS (94) in predicting prognosis.

IHD. CMR-measured MAPSE was a better predictor of major adverse cardiac events (MACE) (death, MI, stroke, heart failure) than LVEF in an ST-elevation myocardial infarction (STEMI) cohort followed up for 3 years (area under curve 0.74 vs 0.61, $p<0.01$) (95). MAPSE <9mm remained a predictor of MACE in models of clinical and imaging risk factors (HR 6.0 [2.5–14.7], $p<0.01$) where LVEF was not associated. Another study of 165 patients post-acute coronary syndrome (ACS) also found MAPSE was a stronger predictor of MACE than LVEF (HR 0.83 [0.73–0.94] per mm increase, $p=0.004$ vs HR 0.96 [0.94–0.99] per % decrease, $p=0.01$) (96). In 271 patients with suspected ACS, those with MAPSE <8mm had a risk ratio of 3.0 ($p<0.001$) for death or heart failure hospitalisation during follow-up compared with the remainder of the cohort (97). In a different cohort with suspected ACS (n=233) lateral MAPSE on CMR predicted MACE during follow up (HR 1.4 [1.1–1.8]) (95), whereas LVEF did not. Conversely, another CMR study of 445 patients 2-4 days post-revascularisation for STEMI found MAPSE was a predictor in univariable analysis (HR 0.80 [0.72–0.89] per mm increase), but not when adjusted for other imaging biomarkers (99). This difference may arise from the model's use of CMR-biomarkers such as infarct size or microvascular obstruction that were not adjusted for in other studies.

In 333 patients with stable IHD, MAPSE was the only imaging marker that correlated independently with mortality (OR 1.6 [1.4–2.0] per mm decrease, $p<0.001$) (100).

Takotsubo cardiomyopathy. Among patients (n=53) with MAPSE <10mm on admission, mortality was higher after 12 months follow-up, but there was no difference within the first year. MAPSE <10mm was a predictor of mortality (HR 5.1 [1.3–19.2], $p<0.01$), whilst LVEF <35% was not (101).

Hypertension. 5.1 years following a CMR (n=1735) lateral MAPSE was associated with increased mortality (HR 1.4 [1.3–1.5] per mm decrease, $p<0.001$) in the whole cohort, as well as in the subgroup analysis of patients with preserved LVEF (HR 1.3 [1.2–1.5] per mm decrease, $p<0.001$) (102). GLS was a predictor of MACE in multivariable analysis, but weaker than MAPSE (HR 1.18 [1.14–1.22]per % increase, $p<0.001$) and LVEF was not a predictor at all. A TTE study (n=156) also reported mean MAPSE was a predictor of MACE in multivariable analysis (HR 0.81 [0.67–0.98 per standard deviation reduction, $p<0.05$) (103).

HCM. MAPSE was lower in those with MACE (death, transplant or ventricular arrhythmia) (6.9±1.9mm vs 10.2±3.1mm, $p=0.01$) with no difference in LVEF between groups ($p=0.86$) (14).

Amyloidosis In 191 patients with wildtype transthyretin amyloidosis, MAPSE was the only imaging-based predictor of mortality in multivariable analysis (HR 0.19 [0.04–0.83], $p=0.003$) (104). A CMR-based study of 68 AL amyloid patients showed lateral MAPSE was a stronger predictor of death or heart transplant (HR 0.23 [0.10–0.56] per mm decrease, $p=0.001$) than LVEF or GLS (105). However, two other TTE studies of patients with AL amyloid found MAPSE predicted death in uni-, but not multivariable analysis (106, 107). MAPSE was a stronger predictor than LVEF in both cohorts, but did not out-perform GLS.

Heart transplant. MAPSE measured by STE at the midpoint of the mitral annulus in 155 patients was a stronger predictor of death/hospitalisation than GLS (HR 0.68 [0.56–0.83] vs

0.76 [0.66–0.87], *p*<0.001) or LVEF (not associated) (52). Moreover, MAPSE was obtainable in a greater proportion (86%) compared to LVEF or GLS (72%) (52).

Pulmonary arterial hypertension (PAH). In 71 patients with PAH, MAPSE by CMR was higher in survivors (12.3±3.0mm vs 10.0±3.0mm, *p*=0.02). MAPSE predicted death or transplantation (HR 1.2 [1.0–1.3] per mm decrease *p*=0.01) whilst LVEF and right ventricular EF were not associated (108).

Septic shock. Two studies found MAPSE to be the sole or strongest imaging biomarker for predicting mortality in multivariable analysis (37,109). LVEF was not a predictor of mortality in any study.

Atrial fibrillation (AF). A study of 160 patients with AF showed MAPSE was a predictor of mortality (OR 1.4 [1.1–1.7] per mm decrease, p<0.01) where LVEF was not. (110).

Acute pulmonary embolism (PE). MAPSE <11mm predicted mortality or the need for advanced therapies in 363 patients with acute PE and preserved LVEF (OR 3.5 [1.4–9.0], *p*=0.01). MAPSE <11mm combined with tricuspid annular plane systolic excursion (TAPSE) <16mm was strongly associated with adverse outcomes (OR 10.8 [3.1–37.8], *p*<0.01). LVEF <50% was also an adverse prognostic marker (OR 4.1 [1.4–12.0], *p*=0.011) (111).

Coronavirus disease-2019 (COVID-19). MAPSE was the only left-heart imaging biomarker that differed in patients who died and those who survived (11±3 vs 12±3mm, *p*=0.006) (112). In multivariable analysis, MAPSE (HR 1.6 [1.2–2.2] per mm decrease, *p*=0.006) and

right atrial volume index (RAVI) were predictors of mortality. Difference in RAVI is likely to represent the higher ventilatory requirements of the more unwell patients.

Quality of evidence assessment

Overall, the studies demonstrated high methodological quality. NOS and modified-NOS scores ranged from 6–9, and all-but-one study was rated as high quality (7 or higher). No studies were rated as low-quality. A full breakdown of individual study scores is provided in **Supplementary Tables S-4–6**.

Discussion

This systematic review found a moderate-to-strong correlation between MAPSE and LVEF, and a moderate correlation between MAPSE and GLS. In cohorts with a normal LVEF, MAPSE was lower in patients with HTN, T2DM, AS, HCM, Marfan's syndrome, hypothyroidism and mixed connective tissue disease compared with matched healthy controls. Measuring MAPSE routinely, and monitoring its change over time in these conditions, may allow detection of early systolic impairment that would otherwise be missed.

In the largest study of general outpatients, MAPSE was the strongest predictor of death or hospitalisation, outperforming LVEF and GLS (15). MAPSE predicted mortality or MACE in cohorts with HFrEF, IHD, Takotsubo cardiomyopathy, HTN, amyloidosis, post-heart transplant, pulmonary hypertension, AF and COVID-19, where LVEF was either a weaker predictor or not associated. MAPSE was also a stronger predictor than GLS in cohorts with hypertension and amyloidosis. Taken together, routine incorporation of MAPSE into clinical studies with any of the above conditions would seem appropriate to identify the most at-risk patients.

A specific clinical context in which MAPSE may provide additional value for guiding treatment is aortic stenosis. In this setting, MAPSE — but not LVEF — has been shown to improve following intervention (69) and is associated with postoperative symptomatic improvement (68). Yet, current guidelines recommend reduced LVEF as an indication for intervention in asymptomatic patients (113). Importantly, long-axis movement can also be assessed using gated cardiac computed tomography (82), which is routinely performed as part of the pre-intervention workup.

Measurement considerations. In this study, the strongest correlation with LVEF was observed using the mean MAPSE derived from lateral, septal, anterior, and inferior sites. The strongest correlation with GLS was found using the mean of lateral and septal MAPSE. Although incorporating additional measurement sites may require more operator-time, our data suggests it may provide greater diagnostic value and a more comprehensive assessment of systolic function. Automated measurements have proven possible using both TTE and CMR, and show good agreement with manual measurements (114). This may be of value particularly in patients with atrial fibrillation, where MAPSE is likely to vary from beat to beat and may require an average of multiple measurements to be taken. MAPSE can also be measured by speckle tracking echocardiography, which automatically tracks and measures annular movement with less angle dependence, but is only available with specific vendor software.

***Limitations of MAPSE*.** The main limitation with MAPSE is the lack of regional assessment of LV function (115), for which visual assessment and strain remain essential. As the use of M-mode on TTE is angle dependent, off-axis views may underestimate MAPSE, reducing

specificity. However, MAPSE can readily be measured in a less angle-dependent fashion using a simple linear caliper applied to a 2D image. MAPSE is also reduced in patients having undergone mitral valve replacement (116), when it may reflect post-surgical changes moreso than inherent LV myocardial function. Finally, as mentioned, widespread application of MAPSE is currently limited by a lack of standardised practice. However, the generation of normal values from large datasets may lead to the inclusion of MAPSE in guidelines, and with it set the standards for acquisition, measurement, and interpretation.

Limitations of this study

Study quality was assessed using the NOS, which, while widely used, is subjective and may not fully capture all sources of bias in observational studies. As aforementioned, there was significant methodological heterogeneity between studies, particularly in the measurement sites and, as well as study populations and outcome definitions. These variations limited the ability to perform a formal quantitative meta-analysis and precluded direct pooling of results. As a result, it is not possible to derive firm numerical thresholds to guide clinical practice currently. Instead, our findings underscore the promising clinical potential of MAPSE.

Conclusions

MAPSE is a marker of global longitudinal LV function and has a strong association with clinical prognosis. Measurement of MAPSE allows assessment of LV systolic function even with compromised echocardiographic image quality. Early systolic impairment that may be missed when using LVEF alone can be detected using MAPSE. MAPSE also aids in prognostication across multiple cardiac conditions including hypertension, aortic stenosis,

and ischaemic heart disease, outperforming LVEF and GLS in several pathologies. Despite the advancement of more sophisticated techniques within cardiac imaging, new studies continue to highlight the clinical information that MAPSE has to offer clinicians and patients. Those contemplating using MAPSE in their clinical practice may consider both the wealth of data supporting its use presented herein, and da Vinci's timeless sage words that "simplicity is the ultimate sophistication" (117).

References

1. Keele KD. Leonardo da Vinci's Corpus of Anatomical Studies. Hist Med. 1980;8:4-5.
2. Zaky A., Grabhorn L., Feigenbaum H. Movement of the mitral ring: a study in ultrasoundcardiography. Cardiovasc Res. 1967;1:121-31.
3. Carlsson M., Ugander M., Heiberg E., Arheden H. The quantitative relationship between longitudinal and radial function in left, right, and total heart pumping in humans. Am J Physiol Heart Circ Physiol. 2007;293:H636-44.
4. Carlsson M., Ugander M., Mosen H. et al. Atrioventricular plane displacement is the major contributor to left ventricular pumping in healthy adults, athletes, and patients with dilated cardiomyopathy. Am J Physiol Heart Circ Physiol. 2007;292:H1452-9.
5. Asgeirsson D,. Hedstrom E., Jogi J. et al. Longitudinal shortening remains the principal component of left ventricular pumping in patients with chronic myocardial infarction even when the absolute atrioventricular plane displacement is decreased. BMC Cardiovasc Disord. 2017;17:208.
6. Robinson S., Rana B., Oxborough D et al. A practical guideline for performing a comprehensive transthoracic echocardiogram in adults: the British Society of Echocardiography minimum dataset. Echo Res Pract. 2020;7:G59-G93.
7. Mitchell C., Rahko P.S., Blauwet L.A. et al. Guidelines for Performing a Comprehensive Transthoracic Echocardiographic Examination in Adults: Recommendations from the American Society of Echocardiography. J Am Soc Echocardiogr. 2019;32:1-64.
8. Galderisi M., Cosyns B., Edvardsen T. et al. Standardization of adult transthoracic echocardiography reporting in agreement with recent chamber quantification, diastolic function, and heart valve disease recommendations: an expert consensus document of the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2017;18:1301-1310.
9. Kramer C.M., Barkhausen. J, Bucciarelli-Ducci C. et al. Standardized cardiovascular magnetic resonance imaging (CMR) protocols: 2020 update. J Cardiovasc Magn Reson. 2020;22:17.
10. Vancheri F., Longo G., Henein M.Y. Left ventricular ejection fraction: clinical, pathophysiological, and technical limitations. Front Cardiovasc Med. 2024;11:1340708.
11. Mizuguchi Y,. Oishi Y., Miyoshi H,. et al. The functional role of longitudinal, circumferential, and radial myocardial deformation for regulating the early impairment of left ventricular contraction and relaxation in patients with cardiovascular risk factors: a study with two-dimensional strain imaging. J Am Soc Echocardiogr. 2008;21:1138-44.
12. Slawinski G., Hawryszko M., Lizewska-Springer A. et al. Global Longitudinal Strain in Cardio-Oncology: A Review. Cancers (Basel). 2023;15:986.
13. Hu K., Liu D., Herrmann S. et al. Clinical implication of mitral annular plane systolic excursion for patients with cardiovascular disease. Eur Heart J Cardiovasc Imaging. 2013;14:205-12.
14. Doesch C., Sperb A., Sudarski S. et al. Mitral annular plane systolic excursion is an easy tool for fibrosis detection by late gadolinium enhancement cardiovascular magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Arch Cardiovasc Dis. 2015;108:356-66.

15. Xue H., Artico J., Davies R.H. et al. Automated in-line artificial intelligence measured global longitudinal shortening and mitral annular plane systolic excursion: reproducibility and prognostic significance. J Am Heart Assoc. 2022;11:e023849.
16. Moher D., Liberati A., Tetzlaff J. et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151:264-9.
17. Hunter J.E., Schmidt F.S. Methods of Meta-Analysis: Correcting Error and Bias in Research Findings. 2nd ed. Newbury Park, California.: Sage, 1990.
18. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, Tugwell P. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute. 2000. Available: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp
19. Herzog R, Álvarez-Pasquin MJ, Díaz C, Del Barrio JL, Estrada JM, Gil Á. Are healthcare workers' intentions to vaccinate related to their knowledge, beliefs and attitudes? A systematic review. *BMC Public Health*. 2013;13:154.
20. Modesti PA, Reboldi G, Cappuccio FP, et al. Panethnic differences in blood pressure in Europe: a systematic review and meta-analysis. *PLoS ONE*. 2016;11(1):e0147601.
21. Carlhall C.J., Lindstrom L, Wranne B., Nylander E. Atrioventricular plane displacement correlates closely to circulatory dimensions but not to ejection fraction in normal young subjects. Clin Physiol. 2001;21:621-8.
22. Wang Y.H., Sun L., Li S.W. et al. Normal reference values for mitral annular plane systolic excursion by motion-mode and speckle tracking echocardiography: a prospective, multicentre, population-based study. Eur Heart J Cardiovasc Imaging. 2023;24:1384-1393.
23. Grue J.F., Storve S., Stoylen A. et al. Normal ranges for automatic measurements of tissue Doppler indices of mitral annular motion by echocardiography. Data from the HUNT3 Study. Echocardiography. 2019;36:1646-1655.
24. Ochs M.M., Fritz T., Andre F. et al. A comprehensive analysis of cardiac valve plane displacement in healthy adults: age-stratified normal values by cardiac magnetic resonance. Int J Cardiovasc Imaging. 2017;33:721-729.
25. Leng S., Zhao X,. Koh A.S. et al. Age-related changes in four-dimensional CMR-derived atrioventricular junction velocities and displacements: Implications for the identification of altered annular dynamics for ventricular function assessment. Int J Cardiol Heart Vasc .2019;22:6-12.
26. Simonson J.S., Schiller N.B. Descent of the base of the left ventricle: an echocardiographic index of left ventricular function. J Am Soc Echocardiogr. 1989;2:25-35.
27. Qin J.X., Shiota T., Tsujino H. et al. Mitral annular motion as a surrogate for left ventricular ejection fraction: real-time three-dimensional echocardiography and magnetic resonance imaging studies. Eur J Echocardiogr. 2004;5:407-15.
28. Elnoamany M.F., Abdelhameed A.K. Mitral annular motion as a surrogate for left ventricular function: correlation with brain natriuretic peptide levels. Eur J Echocardiogr. 2006;7:187-98.
29. Tsang W., Ahmad H., Patel A.R. et al. Rapid estimation of left ventricular function using echocardiographic speckle-tracking of mitral annular displacement. J Am Soc Echocardiogr. 2010;23:511-5.

30. Bazaz R., Edelman K., Gulyasy B., Lopez-Candales A. Evidence of robust coupling of atrioventricular mechanical function of the right side of the heart: insights from M-mode analysis of annular motion. Echocardiography. 2008;25:557-61.
31. Alam M. The atrioventricular plane displacement as a means of evaluating left ventricular systolic function in acute myocardial infarction. Clin Cardiol. 1991;14:588-94.
32. Alam M, Hoglund C, Thorstrand C. Longitudinal systolic shortening of the left ventricle: an echocardiographic study in subjects with and without preserved global function. Clin Physiol 1992;12:443-52.
33. Berg J., Akesson J., Jablonowski R. et al. Ventricular longitudinal function by cardiovascular magnetic resonance predicts cardiovascular morbidity in HFrEF patients. ESC Heart Fail. 2022;9:2313-2324.
34. Turan O., Kocabas A. Disturbed atrial conduction in patients with Duchenne Muscular Dystrophy. Anatol J Cardiol. 2024;28:493-8.
35. Zidan D.H., Helmy T.A. Usefulness of mitral annular plane systolic excursion in assessment of left ventricular systolic function in mechanically ventilated obese patients. J Crit Care. 2016;34:74-6.
36. Shah A., Nanjayya V., Ihle J. Mitral annular plane systolic excursion as a predictor of left ventricular ejection fraction in mechanically ventilated patients. Australas J Ultrasound Med. 2019;22:138-142.
37. Bergenzaun L., Ohlin H., Gudmundsson P. et al. Mitral annular plane systolic excursion (MAPSE) in shock: a valuable echocardiographic parameter in intensive care patients. Cardiovasc Ultrasound. 2013;11:16.
38. Brault C, Zerbib Y, Mercado P et al. Mitral annular plane systolic excursion for assessing left ventricular systolic dysfunction in patients with septic shock. BJA Open 2023;7:100220.
39. Matos J., Kronzon I., Panagopoulos G., Perk G. Mitral annular plane systolic excursion as a surrogate for left ventricular ejection fraction. J Am Soc Echocardiogr. 2012;25:969-74.
40. Lopez-Candales A., Hernandez-Suarez D.F., Lopez Menendez F. Mitral annular dynamics and left ventricular diastole. Cardiol Res. 2017;8:228-231.
41. Hernandez-Burgos P.M., Lopez-Menedez F., Candales M.D., Lopez-Candales A. Is mitral annular ascent useful in studying left ventricular function through left atrio-ventricular interactions? Indian Heart J. 2018;70:368-372.
42. Stenberg Y, Wallinder L, Lindberg A, et al. Preoperative point-of-care Aasessment of left ventricular systolic dysfunction With Ttansthoracic echocardiography. Anesth Analg. 2021;132:717-725.
43. Ozer P.K., Govdeli E.A., Demirtakan Z.G. et al. The relation of echo-derived lateral MAPSE to left heart functions and biochemical markers in patients with preserved ejection fraction: Short-term prognostic implications. J Clin Ultrasound. 2022;50:593-600.
44. Magdy G., Hamdy E., Elzawawy T., Ragab M. Value of mitral annular plane systolic excursion in the assessment of contractile reserve in patients with ischemic cardiomyopathy before cardiac revascularization. Indian Heart J. 2018;70:373-378.
45. Cirin L., Luca CT., Vacarescu C., et al. Added value of MAPSE to assess LV systolic function in conventional cardiac pacing. J Clin Med. 2025;14:6880.

46. Ballo P., Bocelli A., Motto A., Mondillo S. Concordance between M-mode, pulsed tissue Doppler, and colour tissue Doppler in the assessment of mitral annulus systolic excursion in normal subjects. Eur J Echocardiogr. 2008;9:748-53.
47. Mondillo S., Galderisi M., Ballo P. et al. Left ventricular systolic longitudinal function: comparison among simple M-mode, pulsed, and M-mode color tissue Doppler of mitral annulus in healthy individuals. J Am Soc Echocardiogr 2006;19:1085-91.
48. Liu L., Tuo S., Zhang J. et al. Reduction of left ventricular longitudinal global and segmental systolic functions in patients with hypertrophic cardiomyopathy: Study of two-dimensional tissue motion annular displacement. Exp Ther Med. 2014;7:1457-1464.
49. Chiu D.Y., Abidin N,. Hughes J., et al. Speckle tracking determination of mitral tissue annular displacement: comparison with strain and ejection fraction, and association with outcomes in haemodialysis patients. Int J Cardiovasc Imaging. 2016;32:1511-8.
50. Blixt P.J., Chew M.S., Ahman R et al. Left ventricular longitudinal wall fractional shortening accurately predicts longitudinal strain in critically ill patients with septic shock. Ann Intensive Care. 2021;11:52.
51. Iwakura K, Onishi T, Okamura A, et al. Tissue Mitral Annular Displacement in Patients With Myocardial Infarction — Comparison With Global Longitudinal Strain. *Circ Rep*. 2021;3(9):530–539. doi:10.1253/circrep.CR-21-0076
52. Ji X,. Zhang Y., Xie Y. et al. Feasibility and prognostic value of tissue motion annular displacement in patients with heart transplantation. Echocardiography. 2024;41:e15809.
53. Wenzelburger F.W., Tan Y.T,. Choudhary F.J., et al. Mitral annular plane systolic excursion on exercise: a simple diagnostic tool for heart failure with preserved ejection fraction. Eur J Heart Fail. 2011;13:953-60.
54. Teraguchi I., Hozumi T,. Takemoto K. et al. Assessment of decreased left ventricular longitudinal deformation in asymptomatic patients with organic mitral regurgitation and preserved ejection fraction using tissue-tracking mitral annular displacement by speckle-tracking echocardiography. Echocardiography. 2019;36:678-686.
55. Luszczak J., Olszowska M., Drapisz S. et al. Assessment of left ventricle function in aortic stenosis: mitral annular plane systolic excursion is not inferior to speckle tracking echocardiography derived global longitudinal peak strain. Cardiovasc Ultrasound. 2013;11:45.
56. Lopez-Candales A., Hernandez-Suarez D.F., Menendez F.L. Are measures of left ventricular longitudinal shortening affected by left atrial enlargement? Cardiol Res. 2018;9:1-6.
57. Zhang W., Azibani F,. Libhaber E. et al. The role of conventional echocardiographic parameters on detecting subclinical anthracycline therapy related cardiac dysfunction-The SATRACD study. Front Cardiovasc Med. 2022;9:966230.
58. Nemes A, Kalapos A, Domsik P, Forster T. Longitudinal systolic excursion of the mitral annular plane and left ventricular rotational mechanics are associated in healthy adults: three-dimensional speckle-tracking echocardiography-derived insights from the MAGYAR-Healthy Study. *Journal of Ultrasound in Medicine*. 2014;33(11):1861–1866.

59. Xiao H.B., Kaleem S., McCarthy C., Rosen S.D. Abnormal regional left ventricular mechanics in treated hypertensive patients with 'normal left ventricular function'. Int J Cardiol. 2006;112:316-21.
60. Koulouris S.N., Kostopoulos K.G., Triantafyllou K.A. et al. Impaired systolic dysfunction of left ventricular longitudinal fibers: a sign of early hypertensive cardiomyopathy. Clin Cardiol. 2005;28:282-6.
61. Ballo P., Cameli M., Mondillo S. et al. Impact of diabetes and hypertension on left ventricular longitudinal systolic function. Diabetes Res Clin Pract. 2010;90:209-15.
62. Salas-Pacheco J.L., Lomeli-Sanchez O., Baltazar-Gonzalez O., Soto M.E. Longitudinal systolic dysfunction in hypertensive cardiomyopathy with normal ejection fraction. Echocardiography. 2022;39:46-53.
63. Li Y., Wu C., Li Y. Feasibility study of automated cardiac motion quantification to assess left ventricular function in type 2 diabetes. Sci Rep. 2023;13:1101.
64. Loncarevic B., Trifunovic D,. Soldatovic I., Vujisic-Tesic B. Silent diabetic cardiomyopathy in everyday practice: a clinical and echocardiographic study. BMC Cardiovasc Disord. 2016;16:242.
65. Tromba L, Tartaglia F, Carbotta S et al. The role of sleeve gastrectomy in reducing cardiovascular Risk. Obes Surg. 2017;27:1145-1151.
66. Rydberg E., Gudmundsson P., Kennedy L., Erhardt L., Willenheimer R. Left atrioventricular plane displacement but not left ventricular ejection fraction is influenced by the degree of aortic stenosis. Heart. 2004;90:1151-5.
67. Takeda S., Rimington H., Smeeton N., Chambers J. Long axis excursion in aortic stenosis. Heart 2001;86:52-6.
68. Weidemann F, Herrmann S, Stork S et al. Impact of myocardial fibrosis in patients with symptomatic severe aortic stenosis. Circulation 2009;120:577-84.
69. Kempny A., Diller G.P., Kaleschke G. et al. Longitudinal left ventricular 2D strain is superior to ejection fraction in predicting myocardial recovery and symptomatic improvement after aortic valve implantation. Int J Cardiol. 2013;167:2239-43.
70. Matos J.D., Kiss J.E., Locke A.H., et al. Relation of the mitral annular plane systolic excursion to risk for intervention in initially asymptomatic patients with aortic stenosis and preserved systolic function. Am J Cardiol. 2017;120:2031-2034.
71. Herrmann S., Stork S., Niemann M. et al. Low-gradient aortic valve stenosis myocardial fibrosis and its influence on function and outcome. J Am Coll Cardiol. 2011;58:402-12.
72. Liu D., Hu K., Liebner E. et al. Value of low-dose dobutamine stress echocardiography on defining true severe low gradient aortic stenosis in patients with preserved left ventricular ejection fraction. Int J Cardiovasc Imaging 2018;34:1877-1887.
73. Dursunoglu D., Polat B., Evrengul H. et al. Assessment of systolic function by atrioventricular plane displacement in patients with diastolic dysfunction. Acta Cardiol. 2004;59:409-15.
74. Gromadzinski L., Pruszczyk P. Echocardiographic changes in patients with stage 3-5 chronic kidney disease and left ventricular diastolic dysfunction. Cardiorenal Med. 2014;4:234-43.
75. Taşolar H., Mete T., Cetin M. et al. Mitral annular plane systolic excursion in the assessment of left ventricular diastolic dysfunction in obese adults. Anatol J Cardiol. 2015;15:558-64.

76. Bytyci I., Bajraktari G. Left atrial changes in early stages of heart failure with preserved ejection fraction. Echocardiography. 2016;33:1479-1487.
77. Lopez-Candales A. Automated functional imaging for assessment of left ventricular mechanics in the presence of left ventricular hypertrophy. Echocardiography. 2014;31:605-14.
78. Wierzbowska-Drabik K., Chrzanowski L., Kapusta A. et al. Severe obesity impairs systolic and diastolic heart function - the significance of pulsed tissue Doppler, strain, and strain rate parameters. Echocardiography. 2013;30:904-11.
79. Qureshi A.E., Chaudhary F.U.. Mitral annular plan systolic excursion (MAPSE) underestimates left ventricular systolic function in patients with left ventricular hypertrophy. The Professional Medical Journal 2018;25:1622-6.
80. Fröjdh F., Soundappan D., Sörensson P., et al. Strain measures of the left ventricle and left atrium are composite measures of left heart geometry and function. MedRxiv (Preprint) May 2025.
81. Ozden O., Bingol G., Unlu S., Boyuk F. A cardiac magnetic resonance study: comparison of biventricular longitudinal function in hypertrophic cardiomyopathy patients and normal individuals. Cureus. 2023;15:e34165.
82. Kassab J., Hajj J., Harb R., et al. Mitral annulat function in mitral annular calcification and severe regurgitation. JACC Advances. 2025;4:102161.
83. Kiotsekoglou A., Bajpai A., Bijnens B.H. et al. Early impairment of left ventricular long-axis systolic function demonstrated by reduced atrioventricular plane displacement in patients with Marfan syndrome. Eur J Echocardiogr. 2008;9:605-13.
84. Harries I., Biglino G., Ford K. et al. Prospective multiparametric CMR characterization and MicroRNA profiling of anthracycline cardiotoxicity: A pilot translational study. Int J Cardiol Heart Vasc. 2022;43:101134.
85. Ichikawa N, Nishizaki Y, Miyazaki S et al. Efficacy of mitral annular velocity as an alternative marker of left ventricular global longitudinal strain to detect the risk of cancer therapy-related cardiac disorders. Echocardiography 2024;41:e15877.
86. Botelho L.F.B., de Melo M.D.T., de Almeida A.L.C., Salemi V.M.C. Accuracy of mitral annular plane systolic excursion in diagnosing anthracycline-induced subclinical cardiotoxicity in patients with breast cancer - a retrospective cohort study. Cardiooncology. 2024;10:76.
87. Tafarshiku R., Henein M.Y., Berisha-Muharremi V. et al. Left ventricular diastolic and systolic functions in patients with hypothyroidism. Medicina (Kaunas). 2020;56:524.
88. Berger S.G., Witczak B.N., Reiseter S. et al. Cardiac dysfunction in mixed connective tissue disease: a nationwide observational study. Rheumatol Int. 2023;43:1055-1065.
89. Rangarajan V., Chacko S.J., Romano S .et al. Left ventricular long axis function assessed during cine-cardiovascular magnetic resonance is an independent predictor of adverse cardiac events. J Cardiovasc Magn Reson. 2016;18:35.
90. Romano S., Judd R.M., Kim R.J. et al. Left ventricular long-axis function assessed with cardiac cine MR imaging is an independent predictor of all-cause mortality in patients with reduced ejection fraction: a multicenter study. Radiology. 2018;286:452-460.
91. Svealv B.G., Olofsson E.L., Andersson B. Ventricular long-axis function is of major importance for long-term survival in patients with heart failure. Heart. 2008;94:284-9.

92. Willenheimer R., Cline C., Erhardt L., Israelsson B.. Left ventricular atrioventricular plane displacement: an echocardiographic technique for rapid assessment of prognosis in heart failure. Heart. 1997;78:230-6.
93. Tavazzi G., Colombo C.N.J. Klersy C. et al. Echocardiographic parameters for weaning from Extracorporeal Membrane Oxygenation - the role of longitudinal function and cardiac time intervals. Eur Heart J Cardiovasc Imaging. 2024;26:359-67.
94. Berg J., Jablonowski R., Mohammad M., et al. Ventricular longitudinal shortening is an independent predictor of death in heart failure patients with reduced ejection fraction. Sci Rep. 2021;11:20280.
95. Mayr A., Pamminger M., Reindl M. et al. Mitral annular plane systolic excursion by cardiac MR is an easy tool for optimized prognosis assessment in ST-elevation myocardial infarction. Eur Radiol. 2020;30:620-629.
96. Wang L., Yuan W., Huang X., Zhao X., Zhao X.. Cardiac magnetic resonance-derived mitral annular plane systolic excursion: a robust indicator for risk stratification after myocardial infarction. Int J Cardiovasc Imaging. 2024;40:897-906.
97. Brand B., Rydberg E., Ericsson G., Gudmundsson P., Willenheimer R. Prognostication and risk stratification by assessment of left atrioventricular plane displacement in patients with myocardial infarction. Int J Cardiol 2002;83:35-41.
98. Yan C., Chang Y., Fang-Wu et al. Evaluation of the prognostic value of lateral MAPSE in patients with suspected coronary artery disease. Int J Cardiol Heart Vasc. 2025;56:101567.
99. Holzknecht M., Reindl M., Tiller C. et al. Global longitudinal strain improves risk assessment after ST-segment elevation myocardial infarction: a comparative prognostic evaluation of left ventricular functional parameters. Clin Res Cardiol. 2021;110:1599-1611.
100. Rydberg E., Erhardt L., Brand B., Willenheimer R. Left atrioventricular plane displacement determined by echocardiography: a clinically useful, independent predictor of mortality in patients with stable coronary artery disease. J Intern Med. 2003;254:479-85.
101. El-Battrawy I., Ansari U., Lang S. et al. Risk stratification in Takotsubo syndrome: a role of mitral annular plane systolic excursion. QJM 2018;111:231-236.
102. Romano S., Judd R.M., Kim R.J. et al. Prognostic Implications of Mitral Annular Plane Systolic Excursion in patients with hypertension and a clinical indication for cardiac magnetic resonance imaging: a multicenter study. JACC Cardiovasc Imaging. 2019;12:1769-1779.
103. Ballo P., Barone D., Bocelli A., Motto A., Mondillo S. Left ventricular longitudinal systolic dysfunction is an independent marker of cardiovascular risk in patients with hypertension. Am J Hypertens 2008;21:1047-54.
104. Siepen F.A.D., Bauer R., Voss A. et al. Predictors of survival stratification in patients with wild-type cardiac amyloidosis. Clin Res Cardiol. 2018;107:158-169.
105. Ochs M.M., Fritz T., Arenja N. et al. Regional differences in prognostic value of cardiac valve plane displacement in systemic light-chain amyloidosis. J Cardiovasc Magn. Reson 2017;19:87.
106. Riffel J.H., Mereles D., Emami M. et al. Prognostic significance of semiautomatic quantification of left ventricular long axis shortening in systemic light-chain amyloidosis. Amyloid. 2015;22:45-53.

107. Liu D., Hu K., Stork S. et al. Predictive value of assessing diastolic strain rate on survival in cardiac amyloidosis patients with preserved ejection fraction. PLoS One. 2014;9:e115910.
108. Lindholm A., Kjellstrom B., Seemann F .et al. Atrioventricular plane displacement and regional function to predict outcome in pulmonary arterial hypertension. Int J Cardiovasc Imaging. 2022;38:2235-2248.
109. Havaldar A.A.. Evaluation of sepsis induced cardiac dysfunction as a predictor of mortality. Cardiovasc Ultrasound. 2018;16:31.
110. Rydberg E., Arlbrandt M., Gudmundsson P., et al. Left atrioventricular plane displacement predicts cardiac mortality in patients with chronic atrial fibrillation. Int J Cardiol 2003;91:1-7.
111. Matos J.D. Balachandran I., Heidinger B.H. et al. Mitral annular plane systolic excursion and tricuspid annular plane systolic excursion for risk stratification of acute pulmonary embolism. Echocardiography. 2020;37:1008-1013.
112. Jarori U., Maatman T.K., Maatman B., et al. Mitral annular plane systolic excursion: an early marker of mortality in severe COVID-19. J Am Soc Echocardiogr. 2020;33:1411-1413.
113. Vahanian A., Beyersdorf F., Praz F. et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2022;43:561-632.
114. Fukui M., Hashimoto G., Lopes B.B.C. et al. Association of baseline and change in global longitudinal strain by computed tomography with post-transcatheter aortic valve replacement outcomes. Eur Heart J Cardiovasc Imaging. 2022;23:476-484.
115. Grue J.F., Storve S., Dalen H. et al. Automatic measurements of mitral annular plane systolic excursion and velocities to detect left ventricular dysfunction. Ultrasound Med Biol. 2018;44:168-176.
116. Stoylen A., Skjaerpe T. Systolic long axis function of the left ventricle. Global and regional information. Scand Cardiovasc J. 2003;37:253-8.
117. Goodreads. Leonardo da Vinci > Quotes > Quotable Quote. March 1st 2025. https://www.goodreads.com/quotes/9010638-simplicity-is-the-ultimate-sophistication-when-once-you-have-tasted.

Central graphical abstract: Clinical utility of MAPSE



Central graphic created by authors (DF), individual panels reproduced and labelled with permission from Mayr[89] (CMR), Yu[117] (TOE) and Lorenzatti[118] (CT).

Figure 1. Examples of MAPSE measurement using M-mode echocardiograph in a person with (A) normal systolic function and (b) impaired systolic function. Reproduced with permission from Hu et al[13], 2012.



Abbreviation: MAPSE, mitral annular plane systolic excursion

Figure 2. Example of MAPSE measurement using CMR. MAPSE measurement using CMR on 4-chamber cine view from lateral and septal annulus. Adapted with permission from Mayr et al[89], 2020.



Abbreviations as per **Figure 1.**

Figure 3. Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow chart outlining study selection.



Abbreviations as per **Figure 1.**

Figure 4: Summary of individual studies and meta-correlation between MAPSE and LVEF.



The size of the individual circles denotes the population size. The red diamond denotes the meta-correlation and 95% confidence interval. Studies are colour coded as per measurement site for MAPSE: blue= lateral point on apical 4 chamber view; black= mean of lateral and septal points on apical 4 chamber view; pink= mean of lateral, septal, anterior and inferior points from apical 4 and 2 chamber views; purple= other. Abbreviations: LVEF, ejection fraction, other as per **Figure 1.**

Figure 5: Summary of individual studies and meta-correlation between MAPSE and the absolute value of GLS.



The size individual circles denotes the population size. The red diamond denotes the meta-correlation and 95% confidence interval. Studies are colour coded as per measurement site for MAPSE: blue= lateral point on apical 4 chamber view; black= mean of lateral and septal point on apical 4 chamber view; pink= mean of lateral, septal, anterior, inferior, anteroseptal and inferolateral points from apical 4, 2 and 3chamber views; purple= other.**Abbreviations**: GLS, global longitudinal strain; others as per Figure 1.

Table 1. Summary of studies presenting reference values in healthy subjects

First author's last name	Year	n	% female	Modality	Measurement point*	Normal values per age group: mean± standard deviation values in mm (age range in years)		
Carlhäll (21)	2001	28	0	TTE	Mean lateral, septal, anterior and inferior A4C and A2C	14.7± 2.3 (20-39)		
Ochs (24)	2017	209	43	CMR	Lateral A4C	M: 17±4; F: 16±3 (<30)	M: 16±3; F: 16±4 (30-60)	M: 14±3; F: 14±2 (>60)
Leng (25)	2019	230	52	CMR	Mean: lateral, septal, anterior, inferior, anteroseptal and inferolateral A4C A2C and A3C.	15.2±2.1 (<30)	14.8±2.8 (40-49)	13.7±1.8 (>70)
Grue (23)	2019	1157	53	TTE	Mean: lateral and septal, A4C	M: 15.1±1.9; F: 15.2±1.8 (<40)	M: 14.0±2.2; F: 14.3±2.0 (40-59)	M: 13.2; ±2.1; F: 12.3±2.0 (>60)
Wang (22)	2023	1952	57	TTE	Lateral A4C	15.2 ±2.7 (18-29)	14.9±2.7 (50-59)	14.9±2.6 (>70)

*Lateral point on apical 4 chamber reported where given; otherwise values reported as provided in study

Abbreviations A2C, apical 2 chamber; A3C, apical 3 chamber; A4C, apical 4 chamber; CMR, cardiac magnetic resonance; F, female; M, male; MAPSE, mitral annular plane systolic excursion; TTE, transthoracic echocardiogram

Table 2. Summary of studies comparing MAPSE with other measures of systolic function.								
First author's last name	**Year**	**Group**	**N with pathology**	**N healthy control**	**Modality**	**Measurement point with highest correlation**	**Key findings***	
							r	**Optimal threshold if reported**
Correlation between MAPSE and LVEF								
Simonson (26)	1989	Mixed cardiac pathologies	74	26	TTE	Midpoint A4C	0.84	<8mm -> LVEF<50%: sens: 98%; spec: 82%
Alam (31)	1991	Post-ACS	37		TTE	Mean: lateral, septal, anterior, inferior A2C and A4C (vs radionucleotide angiography LVEF)	0.87	≥10mm -> LVEF≥50% sens 95%; spec 82%
Alam (32)	1992	Post-ACS or HFrEF	34	45	TTE	Mean: lateral, septal, anterior, inferior A2C and A4C	0.96	
Carlhäll (21)	2001	Healthy adults		28	TTE	Mean: lateral, septal, anterior, inferior A2C and A4C	0.22	
Qin (27)	2004	Mixed cardiac pathologies	47		3D TTE/ CMR	Mean: 18 points on mitral annulus (vs CMR LVEF)	0.84	<12mm -> LVEF <50% Sens: 95% spec:85%
Elnoamany (28)	2006	Multiple cardiac pathologies	133	20	TTE	Mean: lateral, septal, anterior, inferior A2C and A4C	0.81	<12mm -> LVEF<50% sens: 90%; spec 88%
Bazaz (30)	2008	Mixed cohort	75		TTE	Lateral A4C	0.87	
Tsang (29)	2010	Multiple cardiac pathologies	60		TTE/CMR	Midpoint 4AC (vs CMR LVEF)	0.77 (0.73)	
Matos (39)	2012	Mixed cohort	300		TTE	Mean of lateral and septal A4C	Males 0.64 Females 0.47	<6mm -> LVEF <30% sens: 92%; spec 85%
Zidan (35)	2016	Obese ventilated patients	60		TTE	Mean: lateral, septal, anterior, inferior A2C and A4C	0.87	
Lopez-Candales (40)	2017	Mixed cohort	100		TTE	Lateral 4AC	0.6	

Magdy (44)	2018	Ischaemic cardiomyopathy LVEF<35%	50		Dobutamine stress TTE	Mean: lateral and septal A4C	Baseline 0.28 Low dose 0.35	Δ ≥2 mm -> contractile reserve >10% sens 68%; spec 59%
Hernandez-Burgos (41)	2018	Mixed cohort	150		TTE	Lateral A4C	0.46	
Shah (36)	2019	Ventilated patients	39		TTE	Lateral 4AC	0.61	>12.5mm -> LVEF >50% sens: 82.1%; spec: 91.7%
Stenberg (42)	2021	POCUS pre-elective operations	100		TTE	Mean: lateral and septal A4C	0.56	<12mm -> LVEF<50% sens: 95%; spec: 80%
Berg (33)	2022	HFrEF	287	20	CMR	Mean: lateral, septal, anterior, inferior, anteroseptal and inferolateral A4C A2C and A3C.	0.65	
Ozer (43)	2022	Consecutive outpatients	512		TTE	Lateral 4AC	0.34	
Bergenzaun (37)	2013	ICU admissions septic shock	50		TTE	Mean: lateral, septal, anterior, inferior A2C and A4C	0.59	
Brault (38)	2023	Ventilated patients with septic shock	71		TTE	Lateral A4C	0.52	
Turan (34)	2024	Duchenne Muscular Dystrophy	55	54	TTE	Mean: lateral and septal A4C	0.71	
Cirin (45)	2025	Patients with PPM	409		TTE	Mean: lateral and septal A4C	0.89	
Correlation between MAPSE and TDI								
Mondillo (47)	2006	Healthy subjects	56		TTE	Mean: lateral, septal, anterior, inferior A2C and A4C	0.54	
Ballo (46)	2008	Healthy subjects	92		TTE	Lateral A4C	0.90	
Correlation between MAPSE and GLS								
Luszczak (55)	2013	Moderate-severe AS	82		TTE	Mean: midpoint of A4C, A3C and A2C	–0.56	
Wenzelburger (53)	2011	HFpEF	62	36	TTE	Mean: lateral and septal A4C	Rest: –0.43 Exercise: –0.59	

Liu (48)	2014	HCM	65	48	TTE (speckle tracking)	Mean: lateral, septal, anterior, inferior, anteroseptal and inferolateral A4C A2C and A3C.	–0.86	
Chiu (49)	2016	Hemodialysis	198		TTE (speckle tracking)	Mean: midpoint of A4C, A3C and A2C	–0.61	
Lopez-Candales (56)	2018	Mixed cohort	75		TTE	Lateral A4C	–0.54	
Teraguchi (54)	2019	Moderate-severe MR	50		TTE (speckle tracking)	Lateral A4C	–0.51	14.6% change in lateral MAPSE -> low GLS Sens: 94%; spec: 94%
Blixt (50)	2021	ICU admissions with septic shock	73		TTE	Mean: lateral and septal A4C	–0.81	
Iwakura (51)	2021	Post-ACS	246		TTE	Mean: midpoint A4C and A2C	–0.71	
Wang (22)	2023	Healthy subjects	1683		TTE	Mid-point A4C (speckle tracking)	–0.35	
Xue (15)	2022	Mixed outpatient cohort	1572		CMR	Mean: lateral, septal, anterior, inferior, anteroseptal and inferolateral A4C A2C and A3C.	–0.63	
Berg (33)	2022	HFrEF	287	20	CMR	Mean: lateral, septal, anterior, inferior, anteroseptal and inferolateral A4C A2C and A3C.	–0.76	
Zhang (57)	2022	Chemotherapy-related cardiotoxicity	200		TTE	Mean: lateral and septal A4C	Baseline: –0.38 Post-chemo: –0.53	Reduction in MAPSE ≥2mm -> 15% drop in GLS Sens: 74.5%; spec 54.9%
Brault (38)	2023	Ventilated patients with septic shock	71		TTE	Septal A4C	–0.64	

Ji (52)	2024	Post-heart transplant	155	49	TTE	Midpoint A4C	–0.71	<9.1mm associated with mortality/ hospitalisation Sens: 94%; spec 58%
Nemes (58)	2025	Healthy subjects	106		TTE	Lateral A4C	-0.35	

All results are statistically significant with a *p* value <0.05 unless stated otherwise. Where multiple results are provided (e.g. from multiple measurement points) the strongest correlation is given.
Abbreviations: A2C, apical 2 chamber; A3C, apical 3 chamber; A4C, apical 4 chamber; ACS, acute coronary syndrome; AUC, area under curve; CABG, coronary artery bypass graft; CMR, cardiac magnetic resonance; LVEF, ejection fraction; HCM, hypertrophic cardiomyopathy; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; MR, mitral regurgitation; POCUS, point of care ultrasound; sens, sensitivity; spec, specificity; PPM, permanent pacemaker; TDI, tissue Doppler; TOE, transesophageal echocardiography; TTE, transthoracic echocardiogram; VTI, velocity time integral.

Table 3. Summary of studies using MAPSE to diagnose left ventricular systolic impairment when LVEF is normal

First author's last name	Year	Group	N pathology	N control	Modality	Measurements taken	Key findings		
							Study subgroup (comparison if not healthy controls)	MAPSE pathology (mm)	MAPSE control (mm)
Xiao (59)	2006	HTN	26	10	TTE	Septal 4AC		13.1±1.5	16.7±2.5
						Lateral 4AC		12.3±2.5	15.3±0.3
Koulouris (60)	2005	HTN	81	50	TTE	Mean: lateral, septal, anterior, inferior A2C and A4C		10.3±3	13.1±1
Ballo (61)	2010	DM/HTN	163 HTN/DM/both	70	TTE	Mean: lateral, septal, anterior, inferior A2C and A4C	DM	13.5±2.3	15.1±2.4
							HTN	13.2±2.2	
							DM+HTN	11.5±3	
Salas-Pacheco (62)	2021	HTN	226	101	TTE	Mean: lateral and septal A4C		13.8±2.2	15.5±2.0
Tromba (65)	2017	Sleeve gastrectomy	45		TTE	Mean: lateral and septal A4C	Pre- and post-sleeve gastrectomy	Median 16	Median 18
Li (63)	2023	T2DM	100	50	TTE		DM>15 years vs controls	13.98±1.1	15.6±0.45
Loncarevic (64)	2016	DM (no HTN)	210	80	TTE	Mean: lateral, septal, anterior, inferior A2C and A4C		16.4±1.6	15.4±2.1
Takeda (67)	2001	AS (all grades)	78	10	TTE	Lateral 4AC	Lower in severe AS vs healthy controls		
						Septal 4AC	Lower in mild, moderate and severe AS vs control		
Rydberg (66)	2004	AS (all grades)	49	133	TTE	Mean: lateral, septal, anterior, inferior A2C and A4C		9.2±2.3	10.7±2.8
Weidemann (68)	2009	Symptomatic severe AS ± fibrosis on CMR	21 (no fibrosis)	21 (severe fibrosis)	TTE	Septal 4AC	Severe fibrosis vs no fibrosis	4.9±1.0	10.7±1.2

Herrmann (71)	2011	Low-flow low-gradient AS	86		TTE	Lateral: and septal A4C	Low-flow low-gradient AS preserved LVEF (vs moderate AS)	5.8±2.2	12.8±1.7
							Low-flow low-gradient AS reduced LVEF (vs moderate AS)	5.0±0.9	
Kempny (69)	2013	Severe AS undergoing TAVI	101		TTE	Lateral A4C	Pre and post-TAVI	9.1±3.2	10.2±3.3
Matos (70)	2017	Severe asymptomatic AS	205		TTE	Mean: lateral, septal, anterior, inferior A2C and A4C	Change in MAPSE requiring intervention scan (vs those not requiring intervention)	2mm reduction	<2mm reduction
Liu (72)	2018	Low-flow low-gradient AS	43	20	TTE	Lateral A4C	Low-flow low-gradient AS reduced LVEF (vs pseudosevere AS)	9.8±2.6	11.6±2.2
Dursunoglu (73)	2004	DD	62	40	TTE	Mean: lateral, septal, anterior, inferior A2C and A4C		12.4±1.4	15.3±1.4
Gromadzinski (74)	2014	CKD±DD	36	34	TTE	Lateral A4C	CKD with DD vs CKD without DD median(range)	13(11–17)	14(11–16)
Wenzelburger (53)	2011	HFpEF (during exercise)	62	36	TTE	Lateral and septal A4C	At rest	10.9±2.1	12.1±2.2
							During exercise	12±2.2	16.2±2.7
Taşolar (75)	2015	High BMI ±DD	40 high BMI+ HFpEF	40 high BMI	TTE	Mean: lateral, septal, anterior, inferior A2C and A4C		11.8±1.6	15.8±1.6
Bytyci (76)	2016	HFpEF	79	29	TTE	Septal		11.8±2.0	14.0±3.0
						Lateral		12.4±3.0	15.0±3.0
Wierbowska-Drabik (78))	2013	Obesity and LVH	27	27	TTE	Lateral A4C		20±4	22±2

Lopez-Candales (77)	2014	Patients with LVH	45	45	TTE	Lateral A4C		12±2	14±2
Qureshi (79)	2018	Patients with LVH	22	43	TTE	Mean: lateral, septal, anterior, inferior A2C and A4C		10.6±0.9	13.2±1.7
Doesch (14)	2015	HCM	88	50	TTE/CMR	Mean: lateral and septal A4C		10.0±3.2	13.3±3.8
Ozden (81)	2023	HCM	36	34	CMR	Mean: lateral and septal A4C		14.5±2.9	11.7±3.2
Kassab (82)	2025	Mitral regurgitation	200	50	CT	Mean midpoint on A3C, A2C and A4C.		9.9±1.3	11.9±1.0
Kiotsekoglou (83)	2008	Marfan's	66	61	TTE	Anterior A2C		13.8±0.3	18.0±0.2
Harries (84)	2022	Anthracycline-related cardiotoxicity	24		CMR	Lateral A4C	Recovery of function post-anthracycline	11.7±1.5 (poor recovery)	15.7±3.1 (good recovery)
Botelho (86)	2024	Anthracycline-related cardiotoxicity	5 (with cardiotoxicity)	56 (without cardiotoxicity)				13.5 [8.8-16.3] *ns	13.3 [12.0-13.8] *ns
Ichikawa (85)	2024	Anthracycline-related cardiotoxicity	56 (with cardiotoxicity)	200 (without cardiotoxicity)	TTE	Mean: lateral and septal A4C		14.0±1.5*ns	13.8±2.6*ns
Tafarshiku (87)	2020	Hypothyroidism	81	22	TTE	Lateral A4C		14.9±0.3	16.6±0.2
Berger (88)	2023	Mixed connective tissue disease	77	59	TTE	Mean: lateral and septal A4C		13.7±2.1	15.3±2.3

* All results presented as mean±standard deviation unless stated; all results are statistically significant with a *p* value <0.05 unless stated otherwise
Written results provided where numerical results not available in manuscripts.
Abbreviations: A2C, apical 2 chamber; A3C, apical 3 chamber; A4C, apical 4 chamber; AS, aortic stenosis; BMI, body mass index; CAD, coronary artery disease; CKD, chronic kidney disease; CT, computed tomography; DD, diastolic dysfunction; DM, diabetes mellitus; LVEF, left ventricular ejection fraction; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction; HTN, hypertension; LGE, late gadolinium enhancement; LVH, left ventricular hypertrophy; ns, not significant; TAVI, transcatheter aortic valve implantation; TTE, transthoracic echocardiogram

Table 4. Studies comparing MAPSE with LVEF or GLS as a prognostic marker

First author's last name	Year	Group	n	Modality	Measurement	Outcome	Key findings*		
							MAPSE HR [95% CI] unless stated	Uni/ Multivariable	Comparison with LVEF or GLS if provided
Rangarajan (89)	2016	General outpatients	400	CMR	Lateral A4C	Death, MI, hospitalisation, revasc	1.344 /2mm decrease	Multi	LVEF not associated‡
Ozer (43)	2022	General outpatients	512	TTE	Lateral A4C	Death, hospitalisation	Hospitalization: OR 0.12 [0.03–0.42] Death 0.01 [0.00–0.52] (>12mm vs <12mm)	Multi	LVEF not associated†: Hospitalization: 0.98 [0.93-1.03] Death: 0.81 [0.66-1.00]
Xue (15)	2023	General outpatients	1572	CMR	Mean lateral, septal, anterior, inferior, anteroseptal, inferoseptal A4C, A2C and A3C	Death, heart failure hospitalisation	Death: 1.6 [1.4–1.9] Hospitalisation: 2.1 [1.7–2.7] /mm decrease	Multi	GLS: death 1.3 [1.1–1.5], hospitalisation 1.8 [1.4–2.3]/ % increase LVEF death 1.2 [1.0–1.4], hospitalisation: 1.7 [1.3–2.1] / % decrease
Willenheimer (92)	1997	HFrEF	181	TTE	Mean lateral, septal, anterior, inferior A2C and A4C	Death	No HR. >10mm -> mortality 0%.		Not performed.
Svealv (91)	2008	HFrEF	228	TTE	Mean lateral and septal A4C	Death	0.80 [0.66–0.97] /mm increase	Multi	Not performed.
Romano (90)	2018	HFrEF	1040	CMR	Lateral A4C	Death	2.1 [1.5–2.8] / mm decrease	Multi	LVEF not associated: 1.0 [0.0-1.10] /% decrease
Tavazzi (93)	2024	HFrEF	76	TTE	Lateral A4C	Successful wean from ECMO	5.48 [2.66–7.80] (>8.9 vs <8.9mm)	Uni (multi not performed)	LVEF not associated: 0.77 [0.64-3.5], <18 vs >18%.
Berg (94)	2021	HFrEF	287	CMR	Mean: lateral, septal, anterior, inferior, anteroseptal and inferolateral A4C A2C and A3C.	Death	1.33/ mm decrease [1.16–1.53]	Multi	GLS not associated in multivariable analysis.

Brand (97)	2002	Post-ACS	271	TTE	Mean lateral, septal, anterior, inferior A2C and A4C	Death	Risk ratio= 3 (lowest quartile vs upper three quartiles)	Multi	Not performed.
Rydberg (100)	2003	Stable CAD	333	TTE	Mean lateral, septal, anterior, inferior A2C and A4C	Death	OR 1.6 [1.4–2.0]/mm decrease	Uni, multivariable associated (value not given)	LVEF not associated‡
Mayr (95)	2020	Day 2 post-STEMI	255	CMR	Lateral and septal A4C	Death; MI; stroke, heart failure	6.0 [2.5–14.7] (<9 vs >9mm).	Multi	LVEF not associated‡
Holzknecht (99)	2021	Post-STEMI (day 2-4 post PCI)	445	CMR	Septal A4C	Death; MI; heart failure	0.80 [0.72–0.89]/ mm increase	Uni (not associated in multivariable)	Uni: LVEF 0.95 [0.93–0.98] Multi: GLS 1.13 [1.01–1.27] both / % increase
Iwakura (51)	2021	Post-ACS	246	TTE	Mean: midpoint A4C and A2C	Death	0.74 [0.57-0.98]/ mm increase	Multi	GLS: 1.30 [1.03-1.64]/ % increase
Wang (96)	2024	Post-ACS	165	CMR	Mean: lateral and septal A4C	Death; MI; stroke; heart failure; ventricular arrhythmia	0.83 [0.73–0.94]/ mm increase	Multi	LVEF 0.96 [0.94–0.99] /% increase
Yan (98)	2024	Suspected CAD	233	CMR	Lateral A4C	Death, MI, hospitalisation, revascularisation	1.4 [1.1–1.8] †	Multi	LVEF not associated‡
El-Battrawy (101)	2018	Takotsubo	53	TTE	Lateral A4C	Death	5.1 [1.3–19.2] MAPSE <10 vs >10mm	Multi	LVEF not associated: 2.5 [0.5-12.4] <35 vs >35%
Romano (102)	2019	HTN	1735	CMR	Lateral A4C	Death	1.4 [1.3–1.5] / mm decrease	Multi	GLS 1.18 [1.14–1.22)† LVEF not associated‡
Ballo (103)	2008	HTN	156	TTE	Mean: lateral, septal, anterior, inferior A2C and A4C	Death; MI; stroke; heart failure; revascularisation	0.81 [0.67–0.98] / 1 standard deviation reduction	Multi	Not performed.
Dem Siepen (104)	2018	Wildtype-TTR amyloidosis	191	TTE		Death	0.19 [0.04–0.83] †	Multi	GLS not associated‡.
Liu (107)	2014	AL amyloidosis	41	TTE	Mean: lateral and septal A4C	Death	1.24 [1.02–1.50]/ mm increase	Uni (not associated in multivariable)	Uni: GLS not associated: 2.3 [0.88-6.03]/ % increase

Riffel (106)	2014	AL amyloidosis	120	TTE	Lateral A4C	Death	0.05 [0.018–0.11]/ 10 mm decrease	Uni (not associated in multivariable)	Multi: GLS 0.76 [0.63–0.91]/ % decrease EF not associated: 0.98 [0.94-1.01]/ % increase
Ochs (105)	2017	AL amyloidosis	68	CMR	Lateral A4C	Death, heart transplant	0.23 [0.10–0.56] /mm increase	Uni (multi not given)	LVEF: 0.95 [0.93–0.98] GLS: 1.12 [1.05–1.19] both / % increase
Ji (52)	2024	Post-heart transplant	155	TTE	Mean: lateral and septal A4C by speckle tracking	Death, hospitalisation	0.68 [0.56–0.83] †	Multi	LVEF not associated‡ GLS: 0.758[0.657–0.874] †
Lindholm (108)	2022	Pulmonary hypertensio n	71	CMR/TTE	Mean: lateral, septal, anterior, inferior, anteroseptal, inferoseptal A4C, A2C and A3C	Death, transplantation	1.16 [1.04–1.29]/ mm decrease	Multi	LVEF not associated‡
Bergenzaun (37)	2013	ICU admissions septic shock	50	TTE	Mean: lateral, septal, anterior, inferior A2C and A4C	28-day mortality	OR 0.67 [0.5–0.9]/ mm increase	Multi	LVEF not associated‡
Havaldar (109)	2018	ICU admissions septic shock	48	TTE	Lateral A4C	Death in ICU	OR 0.02 [0.00–0.69] †	Multi	Not performed
Rydberg (110)	2003	Permanent A fib	160	TTE	Mean: lateral, septal, anterior, inferior A2C and A4C	Death	OR 1.37 [1.10–1.70]/ mm decrease	Multi	LVEF not associated‡
Matos (111)	2020	Acute PE	362	TTE	Mean: lateral, septal, anterior, inferior A2C and A4C	Death, need for thrombolysis or pressors	OR 3.5 [1.4–9.0] <11vs >11mm with preserved LVEF	Multi	LVEF 4.1 [1.4–12.0] <50 vs >50%
Jarori (112)	2020	Severe COVID-19	68	TTE	Mean: lateral and septal A4C	Death	1.6 [1.2–2.2] <10 vs >10mm	Multi	LVEF not associated‡

* All results presented are statistically significant with a p value <0.05 unless stated otherwise. † Threshold not explicitly stated. ‡ HRs not given for non-significant associations
Abbreviations: : A2C, apical 2 chamber; A3C, apical 3 chamber; A4C, apical 4 chamber; ACS, acute coronary syndrome; A fib: atrial fibrillation; CAD, coronary artery disease CMR, cardiac magnetic resonance; COVID-19, coronavirus disease-2019; LVEF, left ventricular ejection fraction; GLS, global longitudinal strain; HR, hazard ratio; HCM, hypertrophic cardiomyopathy; HFrEF, heart failure with reduced ejection fraction; HR, hazard ratio; ICU, intensive care unit; MACE, major adverse cardiac events; MAPSE, mitral annulus systolic plane excursion; OR, odds ratio; PE, pulmonary embolism; STEMI, ST elevation myocardial infarction; TTE, transthoracic echocardiogram; TTR, transthyretin